SARS Antibodies NCP, RBD and S2 in Women Vaccinated with Booster Pfizer Vaccine and Infected in Meantime with SARS-CoV-2

Małgorzata Polz-Dacewicz* and Agata Błaszczuk

Department of Virology, SARS Laboratory, Medical University of Lublin, Poland

^*Correspondance to: Małgorzata Polz-Dacewicz 

 PDF  Full Text DOI: 10.25107/2474-1647.3519

Abstract

The effective immunization plays a key role in preventing the spread of SARS-CoV-2 infection. The case study describes the serum titer of antibodies against NPC, RBD and S2 SARS-CoV-2 in 69-old women, who developed hybrid immunity. She was vaccinated with booster dose of Pfizer vaccine and was twice infected with SARS-CoV-2. Despite vaccination and booster dose, she was re-infected. Five months after the booster dose of the vaccine, serum levels of antibodies to RBD (806 U/mL) and S2 – (452 U/ml) were detected.

Keywords

Cite the article

Polz-Dacewicz M, Błaszczuk A. SARS Antibodies NCP, RBD and S2 in Women Vaccinated with Booster Pfizer Vaccine and Infected in Meantime with SARS-CoV-2. Clin Surg. 2022; 7: 3519..